Bo Hansen - Swedish Orphan Insider

BIOVF -- USA Stock  

USD 29.50  1.05  3.69%

Dr. Bo Jesper Hansen M.D. Ph.D. no longer serves as Chairman of the Board of Directors of Swedish Orphan Biovitrum AB effective as of May 24 2016. He has held this position since April 27 2010. He was Member of the Company Board since 2010. He has also served as Member of the Company Nomination Committee and Scientific Committee and Chairman of the Compensation and Benefits Committee. During the course of his career Mr. Hansen has held various positions within Swedish Orphan International AB from 1993 most recently as Chief Executive Officer . He is Founder of Scandinavian Medical Research and has served as Medical Advisor to Synthelabo Pfizer and Yamanouchi. He serves as Member of the Board of Directors of GenSpera Inc. Newron Pharmaceuticals SpA Orphazyme ApS CMC AB Azanta AS Karolinska Development AB and Ablynx NV. He holds a Medical Doctor degree with a Doctor of Philosophy degree from Koebenhavns Universitet.
Age: 57  Chairman Since 2010  Ph.D    
46 86 97 20 00

Management Efficiency

The company has return on total asset (ROA) of 13.63 % which means that it generated profit of $13.63 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 27.22 % meaning that it generated $27.22 on every $100 dollars invested by stockholders.
The company has accumulated 788.2 K in total debt. Swedish Orphan Biovitrum AB has Current Ratio of 1.96 which is within standard range for the sector.

Similar Executives

Found 14 records


Peter AllenGrifols S A
Robert BradwayAmgen
Robert HuginCelgene Corporation
Clay SiegallSeattle Genetics
David KapplerShire plc
Jeppe ChristiansenNovo Nordisk AS
Stelios PapadopoulosBiogen
John MartinGilead Sciences
Victor RouraGrifols S A
John ShineCSL Limited
Susan KilsbyShire plc
Jeffrey LeidenVertex Pharmaceuticals Incorpor
Joshua BogerVertex Pharmaceuticals Incorpor
Goran AndoNovo Nordisk AS

Entity Summary

Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. Swedish Orphan is traded on OTC Market in USA.Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Tomtebodav?gen 23A and employs 842 people.

Swedish Orphan Biovi Leadership Team

Hans Wigzell, Independent Director
Lennart Johansson, Director
Annette Clancy, Independent Director
Trista Morrison, Vice President - Communications for North America
Kirsti Gjellan, Senior Vice President Manufacturing Operations
Jorgen Winroth, Head of Investor Relations and VP
Milan Zdravkovic, Senior Vice President Head of Research & Development
Rami Levin, Head of North America
Norbert Oppitz, Head of Specialty Care
Hans Schikan, Independent Director
Dennis Pedersen, Senior Vice President Human Resources
Helena Saxon, Director
Anders Edvell, Head of Marketing and Sales
Philip Wood, Head of Haemophilia
Geoffrey McDonough, CEO
Lars Dreioee, Senior Vice President Chief Quality & Compliance Officer
Alan Raffensperger, COO and Sr. VP
Fredrik Berg, Head of Legal and Intellectual Property, Risk- Safety and Environment Management and General Counsel
Fredrik Wetterlundh, Head of Human Resources
BoGunnar Rosenbrand, Director, Employee Representative
Adine Axen, Independent Director
Birgitte Volck, Senior Vice President Chief Medical Officer
MatsOlof Wallin, CFO, Senior Vice President
Stefan Fraenkel, Vice President Head of Corporate Development
Hakan Bjorklund, Independent Chairman of the Board
Cecilia Forberg, Vice President Head of Project and Portfolio Management
Stephen James, Vice President Head of Drug Design and Development
Bo Hansen, Chairman of the Board
Armin Reininger, Senior Vice President Head of Global Medical and Scientific Affairs
Hege Hellstrom, Head of EMENAR
Catarina Larsson, Director, Employee Representative
Henrik Stenqvist, CFO
David Allsop, Director
Elisabeth Svanberg, Director
Torbjorn Hallberg, General Counsel and Head of Legal Affairs
Wills HughesWilson, Senior Vice President and Chief Patient Access Officer
Guido Oelkers, President CEO
Pia Axelsson, Director, Employee Representative
Jeffrey Jonas, Independent Director
Matthew Gantz, Director
Theresa Heggie, Independent Director

Stock Performance Indicators

Current Sentiment - BIOVF

Swedish Orphan Biovi Investor Sentiment

Macroaxis portfolio users are unresponsive in their opinion about investing in Swedish Orphan Biovitrum AB. What is your outlook on investing in Swedish Orphan Biovitrum AB? Are you bullish or bearish?
50% Bullish
50% Bearish

Swedish Orphan Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Swedish Orphan and Amgen. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Portfolio Quick Import module to import or update all your transactions via one easy-to-use interface.